https://www.selleckchem.com/Akt.html Inflammatory bowel disease (IBD) is a chronic inflammatory disorder, primarily of, but not restricted to, the gut. Association between IBD and cancer has been clearly established and is uniformly accepted. IBD patients are at particular risk for intestinal and extraintestinal cancers. There are 2 underlying mechanisms (1) IBD-related inflammation triggers initiation and progression of tumor formation. This particularly results in the development of colorectal cancer, small bowel adenocarcinoma, intestinal lymphoma, anal cancer, and cholangiocarcinoma. (2) Immunosuppressive drugs exhibit carcinogenic properties such as shown for azathioprine and anti-TNF promoting lymphoproliferative malignancies and melanoma and nonmelanoma skin cancer. However, within the last years, IBD-related cancer incidence and prevalence have been decreasing, which might be attributed to better treatment options and surveillance strategies. Moreover, novel biological drugs have been introduced in clinical practice and have dramaticongoing intestinal inflammation and the use of potential carcinogenic drugs. Patients should be educated about the increased risk of cancer with IBD and IBD drugs. However, they should also be informed that most malignancy subtypes are possibly preventable by controlling intestinal inflammation and by using adequate screening strategies.A novel dual-channel chemosensor, 7-allylquinolin-8-ol (AQ), was synthesized based on 8-hydroxyquinoline for selective fluorescence detection of Hg2+ and colorimetric recognition of Cu2+. The chemosensor reacted with Hg2+ and generated a new Hg-containing compound with significantly enhanced fluorescence, which turned from faint blue to strong green. Further experiments indicated that AQ could be used to quantitatively detect Hg2+ via fluorescence spectroscopy with a low detection limit (2.1 nM). The good reversibility of the synthesized chemosensor was also demonstrated using NaBH4. Moreover, AQ